Skip to main content
SpringerLink
Log in

PCA3 in the detection and management of early prostate cancer

  • Review
  • Published:
Tumor Biology

Abstract

Although widely used, the value of prostate-specific antigen (PSA) in the detection of prostate cancer is controversial. The percentage of free PSA increases the specificity of PSA, but results are not enough. Prostate cancer gene 3 (PCA3) has been proposed as an option that may complement these markers in the detection and management of early prostate cancer. Our aim has been to review the value of PCA3 as tumor marker. The available results suggest that PCA3 is particularly useful to select in which patients the biopsy should be repeated when the first biopsy was negative. However, some points should be specified with further studies, including the most appropriate PCA3 cutoff level and the significance of a high PCA3 score in patients with negative biopsy. False-negative results are also a conflictive point in the use of PCA3, because prostate cancer, including aggressive tumors, may be present in patients with a low PCA3 score. Probably, a proper interpretation of this test requires its management together with other tests, through multivariate models for the detection of prostate cancer. On the other hand, several studies showed the relation between PCA3 score and Gleason score, and also the utility of PCA3 to select patients for active surveillance. To summarize, the available studies show the utility of PCA3 in the detection and management of early prostate cancer, although some aspects referred to its use need to be retested after further studies to confirm the actual value and the limitations of this test.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Catalona WJ, Partin AW, Slawin KM, Brawer MK, Flanigan RC, Patel A, et al. Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial. JAMA. 1998;279:1542–7.

    Article  PubMed  CAS  Google Scholar 

  2. Roddam AW, Duffy MJ, Hamdy FC, Ward AM, Patnick J, Price CP, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA level of 2–10 ng/ml: systematic review and meta-analysis. Eur Urol. 2005;48:386–99.

    Article  PubMed  CAS  Google Scholar 

  3. Etzioni R, Penson DF, Legler JM, di Tommaso D, Boer R, Gann PH, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Nat Cancer Inst. 2002;94:981–90.

    Article  PubMed  Google Scholar 

  4. Johansson JE, Andrén O, Andersson SO, Dickman PW, Holmberg L, Magnuson A, et al. Natural history of early, localized prostate cancer. JAMA. 2004;291:2713–9.

    Article  PubMed  CAS  Google Scholar 

  5. Bangma CH, Bul M, van der Kwast TH, Pickles T, Korfage IJ, Hoeks CM, et al. Active surveillance for low-risk prostate cancer. Crit Rev Oncol Hematol. 2012 Aug 6

  6. Hori S, Blanchet JS, McLoughlin J. From prostate-specific antigen (PSA) to precursor PSA (proPSA) isoforms: a review of the emerging role of proPSAs in the detection and management of early prostate cancer. BJU Int. 2012; doi: 10.1111/j.1464-410X.2012.11329.x.

  7. Filella X, Giménez N. Evaluation of [−2] proPSA and Prostate Health Index (phi) for the detection of prostate cancer: a systematic review and meta-analysis. Clin Chem Lab Med. 2012;15:1–11.

    Article  Google Scholar 

  8. Vickers AJ, Gupta A, Savage CJ, Pettersson K, Dahlin A, Bjartell A, et al. A panel of kallikrein marker predicts prostate cancer in a large, population-based cohort followed for 15 years without screening. Cancer Epidemiol Biomarkers Prev. 2011;20:255–61.

    Article  PubMed  CAS  Google Scholar 

  9. Vickers AJ, Cronin AM, Roobol MJ, Savage CJ, Peltola M, Pettersson K, et al. A four-kallikrein panel predicts prostate cancer in men with recent screening: data from the European Randomized Study of Screening for Prostate Cancer, Rotterdam. Clin Cancer Res. 2010;16:3232–9.

    Article  PubMed  CAS  Google Scholar 

  10. Bussemakers MJ, van Bokhoven A, Verhaegh GW, Smit FP, Karthaus HF, Schalken JA, et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res. 1999;59:5975–9.

    PubMed  CAS  Google Scholar 

  11. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, et al. DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res. 2002;62:2695–8.

    PubMed  Google Scholar 

  12. Ferreira LB, Palumbo A, de Mello KD, Sternberg C, Caetano MS, de Oliveira FL, et al. PCA3 noncoding RNA is involved in the control of prostate-cancer cell survival and modulates androgen receptor signaling. BMC Cancer. 2012;12:507. doi:10.1186/1471-2407-12-507.

    Article  PubMed  CAS  Google Scholar 

  13. Groskopf J, Aubin SM, Deras IL, Blase A, Bodrug S, Clark C, et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem. 2006;52:1089–95.

    Article  PubMed  CAS  Google Scholar 

  14. Hessels D, Klein Gunnewiek JM, van Oort I, Karthaus HF, van Leenders GJ, van Balken B, et al. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol. 2003;44:8–15.

    Article  PubMed  CAS  Google Scholar 

  15. Fradet Y, Saad F, Aprikian A, Dessureault J, Elhilali M, Trudel C, et al. uPM3, a new molecular urine test for the detection of prostate cancer. Urology. 2004;64:311–5.

    Article  PubMed  Google Scholar 

  16. Tinzl M, Marberger M, Horvath S, Chypre C. DD3PCA3 RNA analysis in urine—a new perspective for detecting prostate cancer. Eur Urol. 2004;46:182–6.

    Article  PubMed  CAS  Google Scholar 

  17. van Gils MP, Hessels D, van Hooij O, Jannink SA, Peelen WP, Hanssen SL, et al. The time-resolved fluorescence-based PCA3 test on urinary sediments after digital rectal examination: a Dutch multicenter validation of the diagnostic performance. Clin Cancer Res. 2007;13:939–43.

    Article  PubMed  Google Scholar 

  18. Ouyang B, Bracken B, Burke B, Chung E, Liang J, Ho SM. A duplex quantitative polymerase chain reaction assay based on quantification of alpha-methylacyl-CoA racemase transcripts and prostate cancer antigen 3 in urine sediments improved diagnostic accuracy for prostate cancer. J Urol. 2009;181:2508–13.

    Article  PubMed  CAS  Google Scholar 

  19. Mearini E, Antognelli C, Del Buono C, Cochetti G, Giannantoni A, Nardelli E, et al. The combination of urine DD3(PCA3) mRNA and PSA mRNA as molecular markers of prostate cancer. Biomarkers. 2009;14:235–43.

    Article  PubMed  CAS  Google Scholar 

  20. Rigau M, Morote J, Mir MC, Ballesteros C, Ortega I, Sanchez A, et al. PSGR and PCA3 as biomarkers for the detection of prostate cancer in urine. Prostate. 2010;70:1760–7.

    PubMed  Google Scholar 

  21. Rigau M, Ortega I, Mir MC, Ballesteros C, Garcia M, Llauradó M, et al. A three-gene panel on urine increases PSA specificity in the detection of prostate cancer. Prostate. 2011;71:1736–45.

    Article  PubMed  CAS  Google Scholar 

  22. Shen M, Chen W, Yu K, Chen Z, Zhou W, Lin X, et al. The diagnostic value of PCA3 gene-based analysis of urine sediments after digital rectal examination for prostate cancer in a Chinese population. Exp Mol Pathol. 2011;90:97–100.

    Article  PubMed  CAS  Google Scholar 

  23. Salami SS, Schmidt F, Laxman B, Regan MM, Rickman DS, Scherr D, et al. Combining urinary detection of TMPRSS2: ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer. Urol Oncol 2011, May 19.

  24. Sokoll LJ, Ellis W, Lange P, Noteboom J, Elliott DJ, Deras IL, et al. A multicenter evaluation of the PCA3 molecular urine test: pre-analytical effects, analytical performance, and diagnostic accuracy. Clin Chim Acta. 2008;389:1–6.

    Article  PubMed  CAS  Google Scholar 

  25. Ruiz-Aragón J, Márquez-Peláez S. Assessment of the PCA3 test for prostate cancer diagnosis: a systematic review and meta-analysis. Actas Urol Esp. 2010;34:346–55.

    Article  PubMed  Google Scholar 

  26. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011;59:61–71.

    Article  PubMed  Google Scholar 

  27. Deras IL, Aubin SM, Blase A, Day JR, Koo S, Partin AW, et al. PCA3: a molecular urine assay for predicting prostate biopsy outcome. J Urol. 2008;179:1587–92.

    Article  PubMed  Google Scholar 

  28. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol. 2008;54:1081–8.

    Article  PubMed  Google Scholar 

  29. Nakanishi H, Groskopf J, Fritsche HA, Bhadkamkar V, Blase A, Kumar SV, et al. PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance. J Urol. 2008;179:1804–9.

    Article  PubMed  Google Scholar 

  30. Whitman EJ, Groskopf J, Ali A, Chen Y, Blase A, Furusato B, et al. PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume. J Urol. 2008;180:1975–8.

    Article  PubMed  Google Scholar 

  31. van Gils MP, Hessels D. Hulsbergen-van de Kaa CA, Witjes JA, Jansen CF, Mulders PF, et al. Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results. Prostate. 2008;68:1215–22.

    Article  PubMed  Google Scholar 

  32. Vlaeminck-Guillem V, Ruffion A, André J, Devonec M, Paparel P. Urinary prostate cancer 3 test: toward the age of reason? Urology. 2010;75:447–53.

    Article  PubMed  Google Scholar 

  33. Durand X, Xylinas E, Ploussard G, de la Taille A. What information can a PCA3 urine test provide in the diagnosis and treatment of prostate cancer. Journal of Men’s Health. 2011;8:164–9.

    Article  Google Scholar 

  34. Roobol MJ. Contemporary role of prostate cancer gene 3 in the management of prostate cancer. Curr Opin Urol. 2011;21:225–9.

    Article  PubMed  Google Scholar 

  35. Roobol MJ, Schröder FH, van Leeuwen P, Wolters T, van den Bergh RC, van Leenders GJ, et al. Performance of the prostate cancer antigen 3 (PCA3) gene and prostate-specific antigen in prescreened men: exploring the value of PCA3 for a first-line diagnostic test. Eur Urol. 2010;58:475–81.

    Article  PubMed  CAS  Google Scholar 

  36. Roobol MJ, Schröder FH, van Leenders GL, Hessels D, van den Bergh RC, Wolters T, et al. Performance of prostate cancer antigen 3 (PCA3) and prostate-specific antigen in prescreened men: reproducibility and detection characteristics for prostate cancer patients with high PCA3 scores (≥ 100). Eur Urol. 2010;58:893–9.

    Article  PubMed  Google Scholar 

  37. Aubin SM, Reid J, Sarno MJ, Blase A, Aussie J, Rittenhouse H, et al. PCA3 molecular urine test for predicting repeat prostate biopsy outcome in populations at risk: validation in the placebo arm of the dutasteride REDUCE trial. J Urol. 2010;184:1947–52.

    Article  PubMed  Google Scholar 

  38. de la Taille A, Irani J, Graefen M, Chun F, de Reijke T, Kil P, et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions. J Urol. 2011;185:2119–25.

    Article  PubMed  Google Scholar 

  39. Rubio-Briones J, Fernández-Serra A, Ramírez M, Rubio L, Collado A, Casanova J, et al. Resultados del uso expandido del PCA3 score en una población española con sospecha de cáncer de próstata. Actas Urol Esp. 2011;35:589–96.

    Article  PubMed  CAS  Google Scholar 

  40. Ploussard G, Haese A, Van Poppel H, Marberger M, Stenzl A, Mulders PF, et al. The prostate cancer gene 3 (PCA3) urine test in men with previous negative biopsies: does free-to-total prostate-specific antigen ratio influence the performance of the PCA3 score in predicting positive biopsies. BJU Int. 2010;106:1143–7.

    Article  PubMed  Google Scholar 

  41. Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, Shariat SF, et al. A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy. BJU Int. 2012;109:1627–35.

    Article  PubMed  CAS  Google Scholar 

  42. Crawford ED, Rove KO, Trabulsi EJ, Qian J, Drewnowska KP, Kaminetsky JC, et al. Diagnostic performance of PCA3 to detect prostate cancer in men with increased prostate specific antigen: a prospective study of 1,962 cases. J Urol. 2012;188:1726–31.

    Article  PubMed  Google Scholar 

  43. Perdonà S, Bruzzese D, Ferro M, Autorino R, Marino A, Mazzarella C, et al. Prostate health index (phi) and prostate cancer antigen 3 (PCA3) significantly improve diagnostic accuracy in patients undergoing prostate biopsy. Prostate. 2013;73:227–35.

    Article  PubMed  Google Scholar 

  44. Ferro M, Bruzzese D, Perdonà S, Mazzarella C, Marino A, Sorrentino A, et al. Predicting prostate biopsy outcome: prostate health index (phi) and prostate cancer antigen 3 (PCA3) are useful biomarkers. Clin Chim Acta. 2012;413:1274–8.

    Article  PubMed  CAS  Google Scholar 

  45. Stephan C, Jung K, Semjonow A, Schulze-Forster K, Cammann H, Hu X, et al. Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [−2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. Clin Chem. 2013;59:280–8.

    Article  PubMed  CAS  Google Scholar 

  46. Leyten GH, Hessels D, Jannink SA, Smit FP, de Jong H, Cornel EB, et al. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer. Eur Urol. 2012 Nov 15. doi: 10.1016.

  47. Tomlins SA, Aubin SM, Siddiqui J, Lonigro RJ, Sefton-Miller L, Miick S, et al. Urine TMPRSS2:ERG fusion transcript stratifies prostate cancer risk in men with elevated serum PSA. Sci Transl Med. 2011;3:94ra72.

    Google Scholar 

  48. Ankerst DP, Groskopf J, Day JR, Blase A, Rittenhouse H, Pollock BH, et al. Predicting prostate cancer risk through incorporation of prostate cancer gene 3. J Urol. 2008;180:1303–8.

    Article  PubMed  Google Scholar 

  49. Chun FK, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram. Eur Urol. 2009;56:659–67.

    Article  PubMed  Google Scholar 

  50. Auprich M, Bjartell A, Chun FK, de la Taille A, Freedland SJ, Haese A, et al. Contemporary role of prostate cancer antigen 3 in the management of prostate cancer. Eur Urol. 2011;60:1045–54.

    Article  PubMed  CAS  Google Scholar 

  51. Perdonà S, Cavadas V, Di Lorenzo G, Damiano R, Chiappetta G, Del Prete P, et al. Prostate cancer detection in the “grey area” of prostate-specific antigen below 10 ng/ml: head-to-head comparison of the updated PCPT calculator and Chun’s nomogram, two risk estimators incorporating prostate cancer antigen 3. Eur Urol. 2011;59:81–7.

    Article  PubMed  Google Scholar 

  52. Hansen J, Auprich M, Ahyai SA, de la Taille A, van Poppel H, Marberger M, et al. Initial prostate biopsy: development and internal validation of a biopsy-specific nomogram based on the prostate cancer antigen 3 assay. Eur Urol. 2012 Jul 20.

  53. Ng CF, Yeung R, Chiu PK, Lam NY, Chow J, Chan B. The role of urine prostate cancer antigen 3 mRNA levels in the diagnosis of prostate cancer among Hong Kong Chinese patients. Hong Kong Med J. 2012;18:459–65.

    PubMed  CAS  Google Scholar 

  54. Ochiai A, Okihara K, Kamoi K, Oikawa T, Shimazui T, Murayama SI, et al. Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy. BJU Int. 2013 Jan 18. doi: 10.1111/j.1464-410X.2012.11683.x

  55. Salagierski M, Mulders P, Schalken JA. Predicting prostate biopsy outcome using a PCA3-based nomogram in a Polish cohort. Anticancer Res. 2013;33:553–7.

    PubMed  Google Scholar 

  56. Auprich M, Chun FK, Ward JF, Pummer K, Babaian R, Augustin H, et al. Critical assessment of preoperative urinary prostate cancer antigen 3 on the accuracy of prostate cancer staging. Eur Urol. 2011;59:96–105.

    Article  PubMed  Google Scholar 

  57. Ploussard G, Durand X, Xylinas E, Moutereau S, Radulescu C, Forgue A, et al. Prostate cancer antigen 3 score accurately predicts tumour volume and might help in selecting prostate cancer patients for active surveillance. Eur Urol. 2011;59:422–9.

    Article  PubMed  Google Scholar 

  58. van Poppel H, Haese A, Graefen M, de la Taille A, Irani J, de Reijke T, et al. The relationship between Prostate Cancer gene 3 (PCA3) and prostate cancer significance. BJU Int. 2012;109:360–6.

    Article  PubMed  Google Scholar 

  59. Durand X, Xylinas E, Radulescu C, Haus-Cheymol R, Moutereau S, Ploussard G, et al. The value of urinary prostate cancer gene 3 (PCA3) scores in predicting pathological features at radical prostatectomy. BJU Int. 2012;110:43–9.

    Article  PubMed  Google Scholar 

  60. Augustin H, Mayrhofer K, Pummer K, Mannweiler S. Relationship between prostate cancer gene 3 (PCA3) and characteristics of tumor aggressiveness. Prostate. 2012; doi: 10.1002/pros.22558.

  61. Liss MA, Santos R, Osann K, Lau A, Ahlering TE, Ornstein DK. PCA3 molecular urine assay for prostate cancer: association with pathologic features and impact of collection protocols. World J Urol. 2011;29:683–8.

    Article  PubMed  CAS  Google Scholar 

  62. Hessels D, van Gils MP, van Hooij O, Jannink SA, Witjes JA, Verhaegh GW, et al. Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer. Prostate. 2010;70:10–6.

    Article  PubMed  CAS  Google Scholar 

Download references

Conflicts of interest

None

Author information

Authors and Affiliations

  1. Department of Biochemistry and Molecular Genetics (CDB), IDIBAPS Hospital Clinic, C/ Villarroel, 170, 08036, Barcelona, Catalonia, Spain

    Xavier Filella, Laura Foj, Montserrat Milà, Josep M. Augé, Rafael Molina & Wladimiro Jiménez

Authors
  1. Xavier Filella
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura Foj
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Montserrat Milà
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Josep M. Augé
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Rafael Molina
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wladimiro Jiménez
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Xavier Filella.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Filella, X., Foj, L., Milà, M. et al. PCA3 in the detection and management of early prostate cancer. Tumor Biol. 34, 1337–1347 (2013). https://doi.org/10.1007/s13277-013-0739-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-013-0739-6

Keywords

Search

Navigation